Understanding LL-37 Delivery Methods

LL-37 is a 37-amino-acid antimicrobial peptide from the cathelicidin family. As a peptide, its delivery method directly impacts how much active compound reaches its target tissues. Unlike small-molecule drugs that can survive stomach acid easily, peptides are proteins, and proteins are what your digestive system is designed to break down .

This fundamental reality shapes the entire oral vs injection discussion for LL-37 and most other therapeutic peptides.

LL-37 Injection: The Standard Route

How It Works

Subcutaneous injection places LL-37 directly into the tissue beneath the skin, where it is absorbed into the bloodstream and lymphatic system. This bypasses the digestive tract entirely, preserving the peptide's structure and biological activity.

Bioavailability

Subcutaneous injection of peptides generally achieves bioavailability of 65-95%, depending on the specific molecule and injection site . For LL-37, this means the vast majority of what you inject reaches circulation in its active form.

Advantages of Injection

• Predictable dosing: You know how much active LL-37 enters your system.
• Systemic distribution: The peptide can reach tissues throughout the body, including skin, lungs, and mucosal surfaces where it exerts antimicrobial effects.
• Established protocols: Most clinical and research protocols for LL-37 use subcutaneous injection, so dosing guidance is based on this route.
• Rapid onset: Peak plasma levels are typically reached within 1 to 2 hours after subcutaneous administration.

Disadvantages of Injection

• Requires injection technique: Patients must learn proper subcutaneous injection and sterile handling.
• Injection site reactions: Mild redness, swelling, or discomfort at the injection site is common, particularly with LL-37 due to its immunomodulatory nature.
• Storage requirements: Injectable LL-37 must be properly reconstituted and refrigerated. See our LL-37 storage instructions guide.
• Needle aversion: Some patients find daily injections burdensome or anxiety-inducing.

LL-37 Oral Administration: Current Status

The Challenge

Oral delivery of LL-37 faces a major biological obstacle: the gastrointestinal tract is designed to break down peptides and proteins into individual amino acids. Gastric acid (pH 1.5-3.5), pepsin, trypsin, and other proteolytic enzymes in the stomach and small intestine will degrade unprotected LL-37 before it can be absorbed into the bloodstream .

Estimates suggest that unprotected oral peptide bioavailability is typically less than 1-2% of the administered dose. For a peptide like LL-37 that is dosed in microgram quantities, this level of loss makes standard oral administration impractical for systemic effects.

Emerging Oral Delivery Technologies

Researchers are exploring several strategies to improve oral peptide delivery:

• Enteric coatings: Capsules that resist stomach acid and dissolve in the small intestine, protecting the peptide through the harshest part of digestion.
• Permeation enhancers: Compounds that temporarily increase intestinal wall permeability to allow larger molecules to pass through.
• Nanoparticle encapsulation: Packaging LL-37 in lipid or polymer nanoparticles that shield it from enzymatic degradation.
• Mucoadhesive formulations: Preparations that adhere to the intestinal lining, increasing contact time and absorption.

These technologies are in various stages of research. As of 2026, no oral LL-37 formulation has been validated in large-scale human trials for systemic delivery .

When Oral Might Make Sense

There is one scenario where oral LL-37 has a theoretical advantage: targeting the gut itself. If the goal is to deliver antimicrobial activity directly to the intestinal lining, oral administration could place the peptide exactly where it is needed. Some researchers are investigating oral LL-37 for conditions like inflammatory bowel disease and gut dysbiosis, where local activity in the GI tract is the objective rather than systemic absorption .

Side-by-Side Comparison

Our Recommendation

For most patients seeking the immune-modulating and antimicrobial benefits of LL-37, subcutaneous injection remains the recommended delivery method. The bioavailability advantage is simply too large to ignore. When you inject 100 mcg of LL-37 subcutaneously, the vast majority reaches your bloodstream. An equivalent oral dose would deliver a tiny fraction of that amount to systemic circulation.

If needle aversion is a significant concern, we encourage you to review our injection technique guides. Most patients find that with proper instruction, subcutaneous injection becomes routine within the first week. The needles used are very small (typically 29-31 gauge insulin syringes) and the injection itself is brief.

If you are specifically interested in LL-37 for gut health applications, discuss oral formulation options with your physician. Enteric-coated preparations may offer localized benefits, though this remains an area of active research.

Frequently Asked Questions

Is oral LL-37 effective?

For systemic effects, oral LL-37 has very limited effectiveness due to GI degradation. For localized gut effects, early research is exploring enteric-coated formulations, but this is not yet well-established in clinical practice.

Does LL-37 injection hurt?

Most patients describe the injection as a mild pinch. LL-37 can cause localized redness or warmth at the injection site due to its immune-activating properties, but this is generally mild and resolves within an hour.

Can I switch between oral and injectable LL-37?

Discuss any changes in delivery method with your prescribing physician. The doses are not directly interchangeable due to the large difference in bioavailability. Switching routes requires adjusting your entire protocol.

Are there sublingual LL-37 options?

Sublingual (under the tongue) delivery is being explored for some peptides, as the oral mucosa can absorb certain molecules directly into the bloodstream. For LL-37 specifically, sublingual data is limited and this is not a standard clinical route.

What does Form Blends recommend for LL-37 delivery?

Our physicians typically prescribe subcutaneous injectable LL-37 from licensed compounding pharmacies. This ensures consistent dosing, proven bioavailability, and alignment with established clinical protocols. Your physician will discuss the best approach based on your individual needs.